Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913941 | 0.82 | PDE10A (0.61) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL2169411 | 0.81 | PDE10A (0.47) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL322184 | 0.81 | CYSLTR1 (0.49) | PDE10ACYSLTR2CYSLTR1CYP1A2 | |
| SCHEMBL27856432 | 0.79 | CYSLTR1 (0.47) | PDE10ACYSLTR2CYSLTR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL27834787 | 0.79 | CYSLTR1 (0.47) | PDE10ACYSLTR2CYSLTR1CYP1A2 | |
| Hydrogen Sulfide SCHEMBL27881046 | 0.79 | CYSLTR1 (0.47) | PDE10ACYSLTR2CYSLTR1CYP1A2 | |
| Bromide SCHEMBL28854191 | 0.79 | CYSLTR1 (0.47) | PDE10ACYSLTR2CYSLTR1CYP1A2 | |
| SCHEMBL177540 | 0.79 | PDE10A (0.50) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL6798820 | 0.78 | CYSLTR2 (0.53) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL29047068 | 0.77 | PDE10A (0.53) | PDE10ACYSLTR2CYSLTR1CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | claimed |
| EP-2188259-B1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | UNIV HONG KONG POLYTECHNIC (CN) | 2013-11-06 | — | — | EP | claimed |
| CN-101868447-A | Methods of making and administering quinoline derivatives as anticancer agents | UNIV HONG KONG POLYTECHNIC | 2010-10-20 | — | — | CN | claimed |
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | disclosed |
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | disclosed |
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | disclosed |
| EP-2188259-B1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | UNIV HONG KONG POLYTECHNIC (CN) | 2013-11-06 | — | — | EP | disclosed |
| EP-2188259-B1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | UNIV HONG KONG POLYTECHNIC (CN) | 2013-11-06 | — | — | EP | disclosed |
| CN-101868447-A | Methods of making and administering quinoline derivatives as anticancer agents | UNIV HONG KONG POLYTECHNIC | 2010-10-20 | — | — | CN | disclosed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | disclosed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | disclosed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | disclosed |
| EP-1351940-B1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS | INST RECH DEVELOPPEMENT IRD (FR) | 2007-07-25 | — | — | EP | disclosed |
| EP-1351940-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS | Institut de Recherche pour le Développement ( IRD) (FR) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002057238-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD) (FR) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | HCCS, GLS2, NQO1 | PDE10A 4283/4885TLR8 4034/4885CYSLTR2 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.